In the second part of the study, VSV-IFNβ-NIS was combined with the ICI Pembrolizumab, showing preliminary indications of T-cell responses to both the virus and the tumor, thereby suggesting tumor desensitization to treatment. This evidence concerns the gene IFNB1 and neoplasm.